| ISSUE |
PERSPECTIVES/COMMENTARIES |
4 January 2010 Vol.120;1
|
Commentaries
(3)New roles for Notch in tuberous sclerosis
(4)Oxidant stress derails the cardiac connexon connection
(5)Ramping up RANTES in acute response to arterial injury
|
| 1 February 2010 Vol.120;2 |
Commentaries
|
| 1 March 2010 Vol.120;3 |
Commentaries
(3)A nonhuman primate model of chickengunya disease
(4)Lights on for amniopeptidases in cystic kidney disease
(5)Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas
|
| 1 April 2010 Vol.120;4 |
Commentaries
(3)Epithelial-mesenchymal transitions and hepatocarcinogenesis
(4)Monkeying around with cardiac progenitors: hope for the future
(5)Prevention trumps treatment of antibody-mediated transplant rejection
(6)Pathogen-specific antibodies: codependent no longer
|
| 1 May 2010 Vol.120;5 |
Commentaries
(3)p63 and IRF6 brothers in arms against cleft palate
(4)Cryptococci at the brain gate: break and enter or use a Trojan horse?
(5)Caveat mTOR: aberrant signaling disrupts corticogenesis
|
| 1 June 2010 Vol.120;6 |
Commentaries
(3)Revisiting an old acquaintance: role for eIF5A in diabetes
(4)Caught red-handed: uric acid is an agent of inflammation
|
| 1 July 2010 Vol.120;7 |
Commentaries
(3)Radioprotection: smart games with death
(4)CA balancing act for autophagin
(5)Rapid progress for non-nuclear estrogen receptor signaling
|
| 8 August 2010 Vol.120;8 |
Commentaries
(3)Seeing red: flushing out instigators of niancin-associated skin toxicity
(4)PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
(5)Semaphorin 3E, an exception to the rule
|
| 1 September 2010 Vol.120;9 |
Commentaries
(3)Too much PABP,too little translation
(4)Transgenic animals may help resolve a sticky situation in cystic fibrosis
(5)Reconstructing neural circuits using transplanted neural stem in the injured spinal cord
(6)Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue
(7)From skin cells to hepatocytes: advances in application of iPS cell technology
|
| 1 October 2010 Vol.120;10 |
Commentaries
(3)In obesity and weight loss, all roads lead to mighty the macrophage
(4)c-Maf and you won't see fat
|
| 1 November 2010 Vol.120;11 |
Commentaries
(3)WT1: a weak spot in KRAS-induced transformation
(4)Are there more tricks in the bag for treating thrombocytopenia?
(5)New therapy to revert dysfunctional antibody responses during HIV-1 infection
(6)Pharmacologic eigenvalues: beating the rap on bone marrow failure
(7)The cellular response to hypoxia: tuning the system with micro RNAs
(8)The magic and mystery of miR-21
|
| 1 December 2010 Vol.120;12 |
Commentaries
(3)Integral role of integrins in Th17 development
(4)A tincture of hepcidin cures all: the potential for hepcidin therapeutics
(5)Can TNF--α boost regulatory T cells?
(6)Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines
(7)Is ryanodine receptor phosphorylation key to the fight or flight response and heart failure?
(8)Learning about genomics and disease from the anucleate human red blood cell
|
